

AMENDMENTS TO THE CLAIMS

Please amend the claims so that they read as follows:

Claims 1-31 (cancelled).

32 (new). A method of inducing an immune response to a tumor in a subject, which method comprises administering total tumor cell RNA to epidermal cells of the subject *in vivo*, in an amount effective to elicit an immune response against the tumor, wherein the total tumor cell RNA is from tumor cells from the subject.

33 (new). The method of claim 32, wherein the tumor is a fibrosarcoma tumor.

34 (new). The method of claim 32, wherein the immune response reduces or inhibits growth of the tumor.

35 (new). A method for protecting a subject from a cancer, which method comprises delivering an immunologically effective amount of total tumor cell RNA to epidermal cells of the subject *in vivo*, wherein the total tumor cell RNA is taken from a tumor associated with the cancer.

36 (new). The method of claim 35, further comprising delivering an immunostimulatory amount of an immune activating or inflammatory cytokine to the subject.

37 (new). A method of inducing an immune response to a tumor in a subject, which method comprises introducing epidermal cells contacted with total tumor cell RNA *in vitro* to the subject, wherein the total tumor cell RNA and the number of epidermal cells is in an amount effective to elicit an immune response against the tumor and the total tumor cell RNA is from tumor cells from the subject.

38 (new). The method of claim 37, wherein the epidermal cells are modified by pulsing the cells with the total tumor cell RNA.

39 (new). The method of claim 37, wherein the tumor is a fibrosarcoma tumor.

40 (new). The method of claim 37, wherein the immune response reduces or inhibits growth of the tumor.

41 (new). A method for protecting a subject from a cancer which method comprises introducing epidermal cells contacted with total tumor cell RNA *in vitro*, to the subject, wherein the total tumor cell RNA is from a tumor associated with the cancer and the total tumor cell RNA and the number of epidermal cells are in an immunologically effective amount.

42 (new). The method of claim 41, further comprising delivering an immunostimulatory amount of an immune activating or inflammatory cytokine to the subject.

43 (new). A method of inducing immune tolerance to an antigen in a subject, which method comprises intravenously administering antigen RNA to the subject in an amount effective to elicit immune tolerance against the antigen, wherein the antigen is an autoantigen, an allergen, or a transplant tissue antigen.

44 (new). The method of claim 43, wherein the RNA is total cellular RNA from tissues containing the antigen.

45 (new). The method of claim 43, wherein the RNA is total cellular mRNA from tissues containing the antigen.

46 (new). The method of claim 43, wherein the RNA is mRNA encoding the antigen.

47 (new). The method of claim 43, wherein the antigen is an autoantigen.

48 (new). The method of claim 43, wherein the antigen is an allergen.

49 (new). The method of claim 43, wherein the antigen is a transplant tissue antigen.